MENU
ALXO
Stock ticker: NASDAQ
PRICE
CHANGE
CAPITALIZATION
ALX Oncology Holdings (ALXO) Ownership - Who owns ALX Oncology Holdings?
ALX Oncology Holdings Inc is a clinical-stage immuno-oncology company focused on helping patients fight cancer by developing a pipeline of product candidates based on expertise in protein engineering and oncology led by the CD47 blocker, evorpacept, currently in phase 1 and 2 clinical trials... Show more
Profile
Industry
N/A
Address
323 Allerton Avenue
Phone
+1 650 466-7125
Employees
72
Web
https://www.alxoncology.com
Details
Group
Domestic Stock Funds
Category
Biotechnology
Capitalization
26.25M
P/E Ratio
N/A
Total Cash
97.83M
Projected Growth
N/A
Total Debt
9.97M
Revenue
N/A
Risk (Beta)
0.26
Dividend Yield
N/A
Total Cash/Share
1.83
Total Debt/Equity
N/A
Revenue/Share
null USD as % of share price
Fundamentals
ALXO
Capitalization
26.3M
P/E Ratio
N/A
Risk (Beta)
0.26
Dividend Yield
N/A
Total Cash
97.8M
Total Cash/Share
1.83
Total Debt
9.97M
Total Debt/Equity
N/A
Projected Growth (PEG Ratio)
N/A
Revenue/Share (as % of the share price)
0%
Revenue
0
ROE
N/A
Book Value
88.3M
P/B Ratio
0.30
Cash Flow
N/A
Earnings
-2.45
Average Daily Volume YTD
N/A
Common Shares Outstanding - Security Level
53K
Current Ratio
5.47
Current Revenue Per Employee
N/A
Dividends Per Share - Security
N/A
EBITDA
-127.45M
Float
N/A
Float - Current
N/A
Gross Income Margin
N/A
Revenue To Assets
-77.96
Shares Held By Institutions
37.2M
Shares Outstanding - Current
53.4M
Total Liabilities
32.6M
Total Volume MTD
N/A
Value
-1
Gain YTD
-70.587
View a ticker or compare two or three
VS
VS
Show more...
Interact to see
Advertisement
Advertisement
A.I.Advisor
published price charts
A.I. Advisor
published General Information
General Information
a clinical stage company, which engages in the research and development of therapies for cancer patients
Industry Biotechnology
Profile
Fundamentals
Details
Industry
N/A
Address
323 Allerton Avenue
Phone
+1 650 466-7125
Employees
72
Web
https://www.alxoncology.com